Linked Life Data

2971358

Source:http://linkedlifedata.com/resource/pubmed/id/2971358

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2971358rdf:typepubmed:Citationlld:pubmed
pubmed-article:2971358lifeskim:mentionsumls-concept:C0031937lld:lifeskim
pubmed-article:2971358lifeskim:mentionsumls-concept:C0033497lld:lifeskim
pubmed-article:2971358lifeskim:mentionsumls-concept:C1415803lld:lifeskim
pubmed-article:2971358lifeskim:mentionsumls-concept:C0022203lld:lifeskim
pubmed-article:2971358lifeskim:mentionsumls-concept:C1151015lld:lifeskim
pubmed-article:2971358lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:2971358lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:2971358pubmed:issue18lld:pubmed
pubmed-article:2971358pubmed:dateCreated1988-10-24lld:pubmed
pubmed-article:2971358pubmed:abstractTextThe interactions of the stereoisomers of pindolol and propranolol with 5-hydroxytryptamine1A (5-HT1A) binding sites and adenylate cyclase activity were examined in rat hippocampus. (-)Pindolol and (-)propranolol displayed high affinity for 5-HT1A binding sites, and their affinities were not affected significantly by the addition of 10(-4) M GTP to the radioligand assay. The selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased forskolin-stimulated adenylate cyclase activity. The (-)isomers of pindolol and propranolol did not affect basal or forskolin-stimulated activity but, at a concentration of 10(-5) M, they reversed the 8-OH-DPAT inhibition of the forskolin-stimulated cyclase activity. The (+)isomers were less potent in producing this effect. These data suggest that (-)pindolol and (-)propranolol are potent antagonists at 5-HT1A receptors in rat hippocampus.lld:pubmed
pubmed-article:2971358pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:languageenglld:pubmed
pubmed-article:2971358pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:citationSubsetIMlld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2971358pubmed:statusMEDLINElld:pubmed
pubmed-article:2971358pubmed:monthSeplld:pubmed
pubmed-article:2971358pubmed:issn0006-2952lld:pubmed
pubmed-article:2971358pubmed:authorpubmed-author:PeroutkaS JSJlld:pubmed
pubmed-article:2971358pubmed:authorpubmed-author:OksenbergDDlld:pubmed
pubmed-article:2971358pubmed:issnTypePrintlld:pubmed
pubmed-article:2971358pubmed:day15lld:pubmed
pubmed-article:2971358pubmed:volume37lld:pubmed
pubmed-article:2971358pubmed:ownerNLMlld:pubmed
pubmed-article:2971358pubmed:authorsCompleteYlld:pubmed
pubmed-article:2971358pubmed:pagination3429-33lld:pubmed
pubmed-article:2971358pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:meshHeadingpubmed-meshheading:2971358-...lld:pubmed
pubmed-article:2971358pubmed:year1988lld:pubmed
pubmed-article:2971358pubmed:articleTitleAntagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers.lld:pubmed
pubmed-article:2971358pubmed:affiliationDepartment of Neurology, Stanford University, CA 94305.lld:pubmed
pubmed-article:2971358pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2971358pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:2971358pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2971358pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2971358lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2971358lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2971358lld:pubmed